| Business Summary | | Amgen,
Inc.
is
a
global
biotechnology
company
that
discovers,
develops,
manufactures
and
markets
human
therapeutics
based
on
advances
in
cellular
and
molecular
biology.
The
Company
manufactures
and
markets
four
human
therapeutic
products,
EPOGEN
(Epoetin
alfa),
NEUPOGEN
(Filgrastim),
INFERGEN
(Interferon
alfacon-1)
and
STEMGEN
(Ancestim).
Amgen
uses
wholesale
distributors
of
pharmaceutical
products
as
the
principal
means
of
distributing
the
Company's
products
to
clinics,
hospitals
and
pharmacies. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Amgen,
Inc.
is
a
global
biotechnology
company
that
discovers,
develops,
manufactures
and
markets
human
therapeutics
based
on
advances
in
cellular
and
molecular
biology.
For
the
six
months
ended
6/01,
revenues
rose
9%
to
$1.89
billion.
Net
income
rose
10%
to
$626.8
million.
Results
reflect
increased
demand
for
Epogen
due
to
growth
in
the
U.S.
dialysis
patient
population.
Results
also
reflect
higher
expenses
incurred
by
Kirin-Amgen
Inc.
last
year. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Kevin Sharer, 53 Chairman,
Pres, CEO | $2.2M | $15.9M | George Morrow, 48 Exec.
VP of Worldwide Sales and Marketing | -- | -- | Dennis Fenton, 49 Exec.
VP, Operations | 1.0M | 6.9M | Richard Nanula, 41 Exec.
VP, Fin., Strategy and Communications | -- | -- | Roger Perlmutter, M.D., Ph.D., 48 Exec.
VP of R&D | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|